Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant - sprookjes - yvandenbroek - TriplyDB

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

http://www.wikidata.org/entity/Q33808135

about

Advancements in the development of subunit influenza vaccines H5 influenza, a global update.Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics.Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.Simplifying influenza vaccination during pandemics: sublingual priming and intramuscular boosting of immune responses with heterologous whole inactivated influenza vaccine.Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms.Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.Effect of influenza A(H5N1) vaccine prepandemic priming on CD4+ T-cell responses.Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.Multi-epitope Models Explain How Pre-existing Antibodies Affect the Generation of Broadly Protective Responses to Influenza A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.Vaccination with drifted variants of avian H5 hemagglutinin protein elicits a broadened antibody response that is protective against challenge with homologous or drifted live H5 influenza virus.Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans.A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens Strategies to guide the antibody affinity maturation process Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus.Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites.High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans.Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States.Avian Influenza A Virus Pandemic Preparedness and Vaccine Development

P2860

Q27010100-1BB8FDCB-C146-43D5-96E9-FDB03D5354BA Q30151309-5CA8C114-19A3-4CF4-90A5-2ABFE1BAD515 Q30202032-7BA83B64-F3DB-4BD9-8A61-456F02CE227D Q30204573-DDEF5BB8-585B-4953-BFCB-AF63B13C2D5D Q30204578-0EEDB246-6C2A-4E3A-8A72-B4C479FAC9C3 Q30358537-28C46B78-FCC3-4CC3-969F-D2EEC45A71CC Q30362811-ABF39347-122A-4F54-B54B-6D2451E8ED81 Q30366045-AFEC5230-0878-42D0-8271-800C60B1FAC2 Q30368474-0A15F478-CE11-4768-84EA-3DA8A8E805EB Q30372087-A209E7E2-B584-493A-8337-8BA89E83F326 Q30388996-191E8785-512B-42A1-A116-432891A0015D Q30389700-E34AF551-6BA8-413E-8A08-B477BCAFE8D5 Q30401247-6D607521-C516-4DC7-8D36-B640D57B2F0A Q30402500-4D7F36B9-C2EF-4404-A612-BCDB57A14F35 Q30407657-F85962CA-F1C0-4766-BB9E-2C6C03CAA596 Q30424758-847B0552-B941-44D7-96C2-E9C2F62E4A04 Q33720317-27BF825B-971D-4ED2-9327-CFBA4BA65B9F Q35685300-193F493D-73A9-4683-A506-59CB5D5E9285 Q35887626-400F5480-A6B7-4573-A14C-8E348A365CA8 Q35910153-1B23D07F-365B-4CFB-B070-7634E1BA87A1 Q36078779-32ABF3FE-548C-4D99-8EDF-C42A2E930D20 Q41932769-97E1EF29-4407-40BA-AD9E-35990722C177 Q47377692-25EE8E91-98CE-4A24-BAE4-3A85F97E1061 Q56561344-BB35251C-8441-4E90-A837-8E3BF57D98DD

P2860

Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant

http://www.wikidata.org/entity/Q33808135

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety and immunogenicity of i ...... schedule and antigenic variant

@ast

Safety and immunogenicity of i ...... schedule and antigenic variant

@en

type

label

Safety and immunogenicity of i ...... schedule and antigenic variant

@ast

Safety and immunogenicity of i ...... schedule and antigenic variant

@en

prefLabel

Safety and immunogenicity of i ...... schedule and antigenic variant

@ast

Safety and immunogenicity of i ...... schedule and antigenic variant

@en

P1433

Q33808135-7FDC8490-A4DE-41E4-8CB2-909FCEE49E55

P1476

Q33808135-FBB82687-F939-4D43-A350-AF6926507512

P2093

Q33808135-053FAC3F-4FC7-4D6B-9676-CB49AD045DFB

Q33808135-096F9ECE-CAD0-484A-9329-D669C47FC2E4

Q33808135-6775575B-45DA-40A6-8D8C-37C98DB11487

Q33808135-84C08FB6-42BA-46CB-8B9C-D83C222B13B8

Q33808135-B48C7896-4DC1-4890-8944-6006C079B1A6

Q33808135-C4928FBC-BB19-4551-B07D-18FB84AC29BA

Q33808135-CAB25E34-225F-4AFE-814D-DEB00AF1DFA1

Q33808135-E04C11E3-92C5-4E32-B0F9-3DDE17E687C7

Q33808135-E7FD4B1F-EEA8-468F-99C5-80E1965567E7

P2860

Q33808135-2107D0A2-1F07-4C7D-B0D8-3AD9B4A0A8BC

Q33808135-22F483E3-9DB3-4B33-894E-705A7469C116

Q33808135-3E6F5772-0303-4CEA-81D2-3C0DDC495D10

Q33808135-78ACD535-D7D2-44C7-9DED-498FD271C10D

Q33808135-8DD08CC5-8F4B-4E4E-B956-425589D0223F

Q33808135-9643B879-BA94-4AC4-9747-F9F3665292DD

Q33808135-A94122BA-E5B8-4918-8F92-952802D3E732

Q33808135-AA670740-D8A4-4C30-B51B-A604B56D516C

Q33808135-BCDB46D8-8683-4E8E-B1A7-C6046477682E

Q33808135-DF40D044-304F-4B31-8304-997D20C2FFA6

P304

Q33808135-8C6F6663-6D7A-4132-9C80-FF0ACD60AD06

P31

Q33808135-A07916C0-2CA1-4BE2-BBB9-EF3E6B404B37

P356

Q33808135-85423DDA-6FD5-4345-8594-085B1C9FA301

P407

Q33808135-A1AD22BB-9E9E-416E-94CF-19A1A9D68D01

P433

Q33808135-BDC46F49-354D-4ECE-BE34-BA6D27AC640F

P478

Q33808135-B34BACBC-C6D4-4C41-ACD6-F062B2358455

P50

Q33808135-01C35C7A-2DC1-4AC0-B316-748AB7672CCE

Q33808135-18DCF147-CBFE-4C3C-8976-66F830DEACD4

Q33808135-778979CD-31B9-48AB-BF76-E1867F28400B

Q33808135-7BA623AC-BFCC-43D9-9006-F98D3B8CA499

Q33808135-EA461BBD-BF13-4F3D-B63E-BF2ADDF06055

P577

Q33808135-BF37557A-EB5E-48A1-83E4-508E71C62F78

P5875

Q33808135-205904B5-A9D6-4A17-9E9C-AA64488724DA

P698

Q33808135-2F0ACC59-4B1E-44ED-AAC6-968D247C3148

P932

Q33808135-97A0BA93-913C-4C7A-97FA-A07500AF6F00

P356

P1433

The Journal of Infectious Diseases

P1476

Safety and immunogenicity of i ...... schedule and antigenic variant

@en

P2093

Heather Hill

http://www.w3.org/2001/XMLSchema#string

Irene Graham

http://www.w3.org/2001/XMLSchema#string

Lisa A Jackson

http://www.w3.org/2001/XMLSchema#string

Mark J Mulligan

http://www.w3.org/2001/XMLSchema#string

Mark Wolff

http://www.w3.org/2001/XMLSchema#string

National Institute of Allergy ...... and Treatment Evaluation Units

http://www.w3.org/2001/XMLSchema#string

Paul Spearman

http://www.w3.org/2001/XMLSchema#string

Robert B Belshe

http://www.w3.org/2001/XMLSchema#string

Sharon E Frey

http://www.w3.org/2001/XMLSchema#string

P2860

Probable person-to-person transmission of avian influenza A (H5N1)

Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans.

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.

Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.

Avian influenza A (H5N1) in 10 patients in Vietnam.

Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population.

P304

666-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIQ093

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P50

Robert M. Jacobson

Srilatha Edupuganti

Harry L Keyserling

P577

2011-01-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49799279

http://www.w3.org/2001/XMLSchema#string

P698

21282194

http://www.w3.org/2001/XMLSchema#string

P932

3071280

http://www.w3.org/2001/XMLSchema#string